Research programme: proteasome inhibitors - NovartisAlternative Names: Proteasome inhibitors research programme - Novartis
Latest Information Update: 20 Jul 2010
At a glance
- Originator Novartis
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Proteasome inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Nov 2001 Preclinical development for Cancer in Switzerland (Unknown route)